News Image

Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance

Provided By Globe Newswire

Last update: Apr 8, 2022

LEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-12 in New Orleans, LA.

Read more at globenewswire.com

AGENUS INC

NASDAQ:AGEN (7/15/2025, 10:08:07 AM)

6.5101

-0.32 (-4.68%)



Find more stocks in the Stock Screener

Follow ChartMill for more